Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori (Q36385174)

13 August 2017

Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori (English)

1 reference

13 August 2017

0 references

Sang-Pil Yun

1

1 reference

13 August 2017

Han Gyung Seon

2

1 reference

13 August 2017

Chang Soo Ok

3

1 reference

13 August 2017

Kwang Ho Yoo

4

1 reference

13 August 2017

Min Kyung Kang

5

1 reference

13 August 2017

Won Hee Kim

6

1 reference

13 August 2017

Chang Il Kwon

7

1 reference

13 August 2017

Kwang Hyun Ko

8

1 reference

13 August 2017

Seong Gyu Hwang

9

1 reference

13 August 2017

Pil Won Park

10

1 reference

13 August 2017

Sung Pyo Hong

11

1 reference

13 August 2017

language of work or name

1 reference

18 October 2012

1 reference

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

4

1 reference

13 August 2017

452-456

1 reference

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Eradication of Helicobacter pylori: are rifaximin-based regimens effective?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Eradication of Helicobacter pylori: recent advances in treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Rifaximin: in vitro and in vivo antibacterial activity--a review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Treatment of H. pylori infection: a review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Eradication of Helicobacter pylori: a clinical update.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Rifampin and rifabutin resistance mechanism in Helicobacter pylori

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Efficacy of the Combination of Tetracycline, Amoxicillin, and Lansoprazole in the Eradication of Helicobacter pylori in Treatment-Naïve Patients and in Patients Who Are Not Responsive to Clarithromycin-Based Regimens: A Pilot Study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

In vitro activity of rifaximin against Helicobacter pylori.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

[Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication].

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

[The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication].

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Towards the ideal regimen for Helicobacter pylori eradication: the search continues

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

High eradication rates of Helicobacter pylori with a new sequential treatment

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Levofloxacin based regimens for the eradication of Helicobacter pylori

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

[Helicobacter pylori eradication therapy in Korea]

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Seroprevalence of Helicobacter pylori in South Korea

21 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493725

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

21 October 2018

1 reference

12 December 2020

The susceptibility of Helicobacter pylori to the rifamycin, rifaximin

1 reference

12 December 2020

Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study

1 reference

12 December 2020

Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures

1 reference

12 December 2020

[Inter-departmental differences in the eradication therapy for Helicobacter pylori infection: a single center study]

1 reference

12 December 2020

In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin

1 reference

12 December 2020

Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

1 reference

12 December 2020

[The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years]

1 reference

12 December 2020

Identifiers

DOI

10.5009/GNL.2012.6.4.452

1 reference

13 August 2017

1 reference

13 August 2017

1 reference